Latest Datamonitor Stories

2008-06-17 12:00:09

Reportlinker.com announces that a new market research report related to the Consumer trends industry is available in its catalogue. http://www.reportlinker.com/p089980/Trends-in-Kids-Nutrition---Opportunities-and-threats-in-the-context-of-escalating-childhood-obesity.html Introduction Datamonitor forecasts that over 35% of European kids aged 5-13 will be overweight or obese by 2012. In the US, this figure will surpass 40% while Asia-Pac, in particular China, is seeing the fastest...

2007-11-21 06:00:15

Research and Markets (http://www.researchandmarkets.com/reports/c74978) has announced the addition of Datamonitor's new report: The HP ALM Radars (Vendor Focus) to their offering. Introduction This brief analyses the strengths and weaknesses of HP's Application Lifecycle Management offering. HP is rated according to its market impact, user sentiment and technology strength. Scope Technology: an assessment of HP's technology based on specific attributes and the availability of...

2007-10-25 12:00:22

Given that BioMarin Pharmaceuticals's Kuvan is potentially the only treatment for the rare genetic metabolic disorder phenylketonuria, Datamonitor believes that Wall Street may be underestimating Kuvan's market potential. Taking into account the high levels of unmet need in this disease, combined with promising late-stage data, Datamonitor predicts US sales of $403 million in 2011 for Kuvan. Phenylketonuria (PKU) is a rare genetic metabolic disorder that affects approximately one in 15,000...

2007-01-26 09:00:44

Salix Pharmaceuticals' antibiotic Xifaxan was approved by the FDA for the treatment of traveler's diarrhea (TD) in 2004. However, the majority of Xifaxan use is accounted for by off-label indications, growth in which is essential to its revenue potential. Taking this into account, Datamonitor forecasts sales of $106 million in 2008, ahead of Wall Street expectations of $76 million in 2008. Xifaxan is an orally administered rifamycin antibacterial that is poorly absorbed by the...

2006-11-16 15:01:30

Allergan's memantine could offer a novel mechanism to slow glaucoma progression if the current phase III trial shows positive data. However, unless the drug demonstrates significant benefits, the high cost of memantine in comparison to available therapies will hinder initial uptake and Datamonitor predicts modest 2008 revenues of $51 million. A disease of the eye that affects over three million US patients, glaucoma causes degeneration of the optic nerve, leading to progressive blindness....

2006-01-16 19:08:50

By Ben Hirschler, European Pharmaceuticals Correspondent LONDON (Reuters) - The first copycat versions of biotech medicines could be approved in Europe later this year, while the United States is unlikely to get them before 2009, according to a report on Tuesday. Independent consultancy Datamonitor said the European Union was making real progress in drawing up rules for biogeneric, or biosimilar, drugs. But the U.S. is lagging notably behind, with opposition from the branded...

Word of the Day
  • A large punch-bowl of the eighteenth century, usually of silver and with a movable rim, and decorated with flutings and a scalloped edge. It was also used for cooling and carrying wine-glasses.
  • A kind of cotton handkerchief having white spots on a colored ground, the spots being produced by a chemical which discharges the color.
This word is possibly named after Monteith (Monteigh), 'an eccentric 17th-century Scotsman who wore a cloak scalloped at the hem.'